GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(40080)

  • GC81733 structure
    GC81733APS-2-79 (Standard)
    CAS: 2002381-25-9
    Purity: >98.00%

    APS-2-79 (Standard) is the analytical standard of APS-2-79.

  • GC81734 structure
    GC81734UCB1244283
    CAS: 300587-89-7
    Purity: >99.50%

    UCB1244283 is a synaptic vesicle glycoprotein 2A ( SV2A ) allosteric modulator.

  • GC81735 structure
    GC81735Tinlarebant
    CAS: 1821327-95-0
    Purity: >98.00%

    Tinlarebant (LBS-008) is an orally active non-retinoid RBP4 (retinol-binding protein 4) antagonist.

  • GC81736 structure
    GC81736(αR)-BI-9787
    CAS: 3043939-19-8
    Purity: >99.00%

    (αR)-BI-9787 is the epimer of BI-9787.

  • GC81737 structure
    GC81737Hydrocortisone phosphate sodium (Standard)
    CAS: 6000-74-4
    Purity: >98.00%

    Hydrocortisone phosphate sodium (Standard) is the analytical standard of Hydrocortisone phosphate sodium.

  • GC81738 structure
    GC81738URAT1 inhibitor 7
    CAS: 1632002-28-8
    Purity: >98.00%

    URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC 50 of 12 nM.

  • GC81739 structure
    GC81739LY 78335
    CAS: 39226-94-3
    Purity: >99.00%

    LY 78335 (DCMB) is a brain-penetrant phenylethanolamine-N-methyltransferase ( PNMT ) inhibitor with a K i of 0.09 μM.

  • GC81740 structure
    GC81740Tonobafusp alfa
    CAS: 3037637-48-9
    Purity: >99.50%

    Tonobafusp alfa is a human immunoglobulin G4-λ targeting human MELTF.

  • GC81752 structure
    GC817528-Deoxylactucin
    CAS: 65725-10-2
    Purity: >95.00%

    8-Deoxylactucin is an orally active sesquiterpene lactone.

  • GC81753 structure
    GC817532′-Hydroxygenistein
    CAS: 1156-78-1
    Purity: >99.50%

    2′-Hydroxygenistein is a natural product that can be isolated from Crotalaria pallida and C.

  • GC81754 structure
    GC81754(E)-FOBISIN101
    CAS: 1370281-06-3
    Purity: >95.50%

    (E)-FOBISIN101 is a 14-3-3 protein-protein interaction ( 14-3-3 protein-protein interaction ) inhibitor, with IC 50 values of 9.3 and 16.4 μM for disrupting the binding of 14-3-3ζ or 14-3-3γ to PRAS40, respectively.

  • GC81755 structure
    GC81755CHIKV-IN-6
    CAS: 1609009-17-7
    Purity: >99.00%

    CHIKV-IN-6 is a selective CHIKV inhibitor with no cytotoxicity to mammalian cells.

  • GC81756 structure
    GC81756GHP-88310
    Purity: >98.00%

    GHP-88310 is an orally active broad-spectrum paramyxovirus and orthomyxovirus inhibitor that targets the L protein - RdRP complex, and exhibits activity against respiratory viruses and viruses of the genus Morbillivirus [1] [2] . GHP-88310 binds to the central cavity of the polymerase protein, blocks replicase and transcriptase activities, interferes with the viral life cycle and inhibits viral replication [1] [2] . GHP-88310 can be used in studies of paramyxovirus infections, including morbillivirus-like diseases, human parainfluenza virus type 3 infection and measles [1] [2] .

  • GC81757 structure
    GC817573-Ethoxy-5,6-dibromosalicylaldehyde
    CAS: 20041-64-9
    Purity: >99.50%

    3-Ethoxy-5,6-dibromosalicylaldehyde is an IRE1/ERN1 inhibitor, with an IC 50 of 0.12 μM, a K i of 71-88 nM, and a K d of 100 nM against the ribonuclease activity of hIRE1α, as well as an IC 50 of 4.8 μM against yeast Ire1.

  • GC81758 structure
    GC81758HDAC11-IN-5
    Purity: >98.00%

    HDAC11-IN-5 is a selective, potent and orally active HDAC11 inhibitor with an IC 50 of 0.021 μM.

  • GC81759 structure
    GC81759Pitstop 2d
    Purity: >97.00%

    Pitstop 2d is a clathrin ( Clathrin ) terminal domain (TD) inhibitor with an IC 50 of 1.7 μM.

  • GC81760 structure
    GC81760Shepherdine
    CAS: 3000-36-0
    Purity: >98.00%

    Shepherdine, a harmala-type indole and tetrahydro-β-carboline alkaloid, is an antioxidant.

  • GC81761 structure
    GC817614-Methoxycinnamic acid ethyl ester
    CAS: 1929-30-2
    Purity: >98.50%

    4-Methoxycinnamic acid ethyl ester (Ethyl p-methoxycinnamate) is an orally active natural compound found.

  • GC81762 structure
    GC81762Mitoflaxone
    CAS: 87626-55-9
    Purity: >99.50%
  • GC81763 structure
    GC81763Coelenterazine TFA
    Purity: >99.00%

    Coelenterazine TFA is a luminescent enzyme substrate for apoaequorin and Renilla luciferase.

  • GC81764 structure
    GC81764ABC transporter modulator-1
    CAS: 3093661-22-1
    Purity: >96.00%

    ABC transporter modulator-1 (Compound I-5) is an ABC transporter expression enhancer.

  • GC81765 structure
    GC81765ABC transporter modulator-2
    CAS: 3093663-15-8
    Purity: >96.00%

    ABC transporter modulator-2 (Compound I-200) is a ABC transporter expression modulator.

  • GC81766 structure
    GC81766ABC transporter modulator-3
    CAS: 3093661-88-9
    Purity: >97.00%

    ABCC6 modulator-3 (Compound I-71) is a ABCC6 activator with an EC 50 < 1 μM.

  • GC81767 structure
    GC81767BAY-1128688
    CAS: 1428988-21-9
    Purity: >98.00%

    BAY-1128688 is a potent, orally active and selective AKR1C3 inhibitor with IC 50 < 2 nM.